Inside Washington: GMP Progress Report

by Jill Wechsler, BioPharm International Six months into its initiative to update manufacturing regulations, FDA announces a raft of changes covering warning letters, inspections, and comparability ? plus a fresh start on Part 11.

Related Content:

Virus Inactivation in the 1990s and into the 21st Century

Using Peptide Maps as Identity and Purity Tests for Lot Release Testing of Recombinant Therapeutic Proteins

Getting Ready for Risk-Based GMPs